BLOG

How Is Adipose Stem Cell Culture Handled in Osaka, Japan?

Published 2026.10.09 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

When people read about adipose-derived stem cell therapy, the part that often feels most mysterious is what happens between the day fat tissue is collected and the day cells are returned by IV infusion. That middle stage, cell culture and processing, is where a small tissue sample becomes a cell preparation. Understanding it helps you ask better questions before you decide anything. This article explains the process in general terms for international patients considering a consultation at Grand Green Osaka Umekita Clinic in Osaka, Japan.

Why does the culture step matter in adipose stem cell therapy?

Fat tissue contains mesenchymal stem cells, but only a small number are present in the few rice-grain-sized pieces collected under local anesthesia. In the treatment described on the clinic’s regenerative medicine page, these cells are cultured and expanded at a specialized facility so that a sufficient number can be prepared for infusion. Because the cells come from your own body (autologous cells), the preparation is made for one person rather than produced as a general-purpose product.

This also means the quality of the culture step is a central part of the overall treatment. Cell numbers, handling conditions, and the way the preparation is checked all depend on the processing facility and its procedures. For that reason, it is reasonable for patients to ask how this stage is managed, rather than focusing only on the infusion itself.

What happens to your cells at a specialized culture facility?

In general terms, the collected fat tissue is sent to a cell processing facility. There, mesenchymal stem cells are separated from the tissue, placed in a controlled culture environment, and allowed to multiply over a period of time. Cells are monitored during this period and prepared for administration when the planned number has been reached.

Details such as the exact culture period, the number of cells prepared, and the schedule between collection and infusion can differ by clinic and by individual circumstances. You should not assume a fixed timeline from general descriptions. Your doctor can explain the plan that applies to your case at the consultation. It is also reasonable to ask how your cells are transported between the clinic and the facility, and how the clinic keeps you informed if the plan changes. Clear communication on these practical points helps you judge whether the overall process is explained in a way you can follow.

How is quality checked before cells are returned?

Cell processing in regenerative medicine generally involves checks at several points. Without presenting specific figures, the kinds of questions that are commonly relevant include the following.

Is the cell preparation checked for contamination before it is used?
Are the number and condition of the cells confirmed before infusion?
How are samples identified and tracked so that your cells are matched to you?
What happens if the preparation does not meet the planned standards?

These are the kinds of points worth raising with your doctor. A clear and consistent explanation of how the clinic and its processing facility handle them is a useful sign that the process is being managed carefully. Even so, quality checks reduce risk but do not remove it, and the risks and possible side effects of any treatment should be discussed individually with a physician.

How does Japanese law shape cell processing?

In Japan, regenerative medicine provided to patients is regulated under the Act on the Safety of Regenerative Medicine. Clinics offering this kind of treatment submit a regenerative medicine provision plan, and cell culture and processing are expected to be carried out at facilities that meet legal requirements. The treatment is provided as a self-pay (non-insured) medical service, so it is not covered by national health insurance.

This legal framework is one reason patients from overseas often look into Japan as a place to learn about regenerative medicine. However, being provided under a legal system does not by itself tell you whether a treatment is suitable for you or how well it may work for you. The law sets a structure for how care is delivered, while medical judgment about your own condition remains with your doctor.

What should you ask at your consultation in Osaka?

Before deciding on adipose stem cell therapy, it can help to prepare a short list of questions about processing and quality. You might ask where the cells are cultured, how long the process usually takes, how your cells are identified, and what the total costs and number of visits would be. Costs, risks, side effects, and whether the treatment is appropriate for you all need to be confirmed through a medical consultation.

Grand Green Osaka Umekita Clinic is located in Umeda, Osaka, and provides an English information page for international patients. If you are traveling from abroad, you can also ask how consultation and follow-up can be arranged around your schedule. Bring your medical records and a list of current medications so that the doctor can review your history properly.

Key takeaways

Cell culture is the stage that turns a small fat sample into the cell preparation used for infusion, so it deserves as much attention as the collection and infusion visits. Ask how the process is checked, how your cells are tracked, and how the treatment fits into Japan’s regenerative medicine rules. Treat general articles as a starting point, not a substitute for individual medical advice. A consultation with a doctor is the right place to discuss whether this self-pay treatment is suitable for you, along with its costs, risks, and expected course. Standard medical care for your condition should also be discussed and not set aside.

Before You Decide

1ConsultationAsk your doctor
2Culture processPrepared at a facility
3Quality checksAsk how they work
4Japanese rulesRegenerative medicine law
5Self-pay careConfirm costs and risks

This figure is a conceptual diagram that summarizes the article

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›